The Development of a Standardized Ki-67 Assay
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
Clinical Pearls
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
- Ki-67 assays are cheaper than molecular tests
- Measuring Ki-67 before treatment and 4-6 weeks into treatment can determine whether or not therapy is working
- In this trial, researchers stained slides in a standardized way and used computer software to analyze them
- Ki-67 measurement with the software was reproducible, though researchers were able to measure Ki-67 in the traditional way if needed
- Further trials are needed to verify this information
<<<
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
